학술논문
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
Document Type
Article
Author
Source
In European Journal of Cancer May 2024 202
Subject
Language
ISSN
0959-8049